TACSTD2 and breast cancer: Sacituzumab govitecan is an antibody-drug conjugate comprised of an antibody against an antigen expressed in most types of breast cancer, the human trophoblast cell-surface antigen 2 (TROP-2), paired with topoisomerase I inhibitor (SN-38) via a patented hydrolyzable linker [37].